{"id":66967,"date":"2026-06-01T15:03:38","date_gmt":"2026-06-01T07:03:38","guid":{"rendered":"https:\/\/flcube.com\/?p=66967"},"modified":"2026-06-01T15:03:39","modified_gmt":"2026-06-01T07:03:39","slug":"cf-pharmtechs-inhaled-sirna-therapy-icf004-receives-nmpa-clinical-approval-for-interstitial-lung-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66967","title":{"rendered":"CF PharmTech&#8217;s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CF PharmTech Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2652:HKG\">HKG: 2652<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>clinical trial approval<\/strong> for <strong>ICF004 inhalation powder<\/strong>, a novel <strong>small interfering RNA (siRNA) drug<\/strong> with potential <strong>first-in-class mechanism of action<\/strong> for the treatment of <strong>interstitial lung disease (ILD)<\/strong>. The therapy will be evaluated in multiple ILD subtypes, including <strong>idiopathic pulmonary fibrosis (IPF)<\/strong> and <strong>progressive pulmonary fibrosis (PPF)<\/strong>, leveraging CF PharmTech&#8217;s proprietary <strong>inhaled dry powder delivery platform<\/strong> to target diseased lung tissue directly while minimizing systemic exposure.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>CF PharmTech Inc. (HKG: 2652)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ICF004 inhalation powder<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Small interfering RNA (siRNA) therapeutic<\/td><\/tr><tr><td><strong>Delivery Method<\/strong><\/td><td>Inhaled dry powder<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Target Indications<\/strong><\/td><td>Interstitial lung disease (ILD), including IPF and PPF<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>01 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule<\/strong>: <strong>ICF004<\/strong> \u2013 innovative <strong>siRNA drug<\/strong> with potential first-in-class mechanism<\/li>\n\n\n\n<li><strong>Delivery Platform<\/strong>: <strong>Inhaled dry powder<\/strong> formulation enabling direct lung delivery<\/li>\n\n\n\n<li><strong>Targeting Strategy<\/strong>: Maximizes drug concentration in <strong>diseased lung areas<\/strong> while minimizing systemic circulation<\/li>\n\n\n\n<li><strong>Preclinical Evidence<\/strong>:<\/li>\n\n\n\n<li><strong>Differential distribution<\/strong>: High lung tissue exposure with low systemic blood exposure<\/li>\n\n\n\n<li><strong>Anti-fibrotic activity<\/strong>: Demonstrated efficacy in preclinical fibrosis models<\/li>\n\n\n\n<li><strong>Safety profile<\/strong>: Favorable tolerability in preclinical studies<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses unmet need in progressive fibrotic lung diseases with limited treatment options<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-amp-market-opportunity\" class=\"wp-block-heading\">Disease Context &amp; Market Opportunity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Interstitial lung disease (ILD)<\/strong> represents a significant unmet medical need in China and globally:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: Estimated <strong>300,000\u2013500,000 ILD patients<\/strong> in China, with IPF accounting for approximately 30% of cases<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Current therapies (pirfenidone, nintedanib) slow but do not halt disease progression and carry significant side effects<\/li>\n\n\n\n<li><strong>Mortality Impact<\/strong>: IPF has a median survival of <strong>3\u20135 years<\/strong> from diagnosis, highlighting urgent need for more effective therapies<\/li>\n\n\n\n<li><strong>Market Potential<\/strong>: Global anti-fibrotic market projected to reach <strong>$8\u201312 billion annually by 2030<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>inhaled delivery approach<\/strong> offers several strategic advantages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Therapy<\/strong>: Direct delivery to affected lung tissue enhances efficacy while reducing systemic toxicity<\/li>\n\n\n\n<li><strong>Patient Compliance<\/strong>: Dry powder inhalation provides convenient outpatient administration<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: First siRNA-based therapy specifically developed for inhaled delivery in fibrotic lung disease<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This clinical approval marks a significant milestone in our mission to develop transformative RNA therapeutics for serious respiratory diseases,&#8221; said Dr. Wang Jian, Chief Executive Officer of CF PharmTech. &#8220;ICF004&#8217;s targeted delivery to diseased lung tissue, combined with its novel siRNA mechanism, has the potential to address the fundamental drivers of fibrosis while offering improved safety compared to current systemic therapies.&#8221;<\/p>\n\n\n\n<h2 id=\"h-strategic-implications-amp-competitive-landscape\" class=\"wp-block-heading\">Strategic Implications &amp; Competitive Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">CF PharmTech&#8217;s entry into the ILD market positions the company at the forefront of <strong>RNA therapeutics innovation<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Success would validate CF PharmTech&#8217;s inhaled siRNA delivery platform for other respiratory indications<\/li>\n\n\n\n<li><strong>First-Mover Advantage<\/strong>: Potential to become the first inhaled siRNA therapy approved for fibrotic lung disease globally<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: Distinct mechanism of action compared to existing anti-fibrotic small molecules<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Positive clinical data could support international regulatory filings in major markets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view ICF004 as a high-potential asset with <strong>peak annual sales potential of $500 million\u2013$1 billion<\/strong> if clinical development proves successful, given the substantial unmet need and premium pricing potential for breakthrough therapies in progressive fibrotic diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities for ICF004. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100044_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060100044_c.\"><\/object><a id=\"wp-block-file--media-0b57ec23-6f8b-4be8-8a8b-effe15097e9d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100044_c.pdf\">2026060100044_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060100044_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0b57ec23-6f8b-4be8-8a8b-effe15097e9d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CF PharmTech Inc. (HKG: 2652) announced that China&#8217;s National Medical Products Administration (NMPA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4154,62,4641],"class_list":["post-66967","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cf-pharmtech","tag-clinical-trial-approval-initiation","tag-hkg-2652"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CF PharmTech&#039;s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CF PharmTech Inc. (HKG: 2652) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for ICF004 inhalation powder, a novel small interfering RNA (siRNA) drug with potential first-in-class mechanism of action for the treatment of interstitial lung disease (ILD). The therapy will be evaluated in multiple ILD subtypes, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), leveraging CF PharmTech&#039;s proprietary inhaled dry powder delivery platform to target diseased lung tissue directly while minimizing systemic exposure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66967\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CF PharmTech&#039;s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease\" \/>\n<meta property=\"og:description\" content=\"CF PharmTech Inc. (HKG: 2652) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for ICF004 inhalation powder, a novel small interfering RNA (siRNA) drug with potential first-in-class mechanism of action for the treatment of interstitial lung disease (ILD). The therapy will be evaluated in multiple ILD subtypes, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), leveraging CF PharmTech&#039;s proprietary inhaled dry powder delivery platform to target diseased lung tissue directly while minimizing systemic exposure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66967\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T07:03:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T07:03:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66967#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66967\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CF PharmTech&#8217;s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease\",\"datePublished\":\"2026-06-01T07:03:38+00:00\",\"dateModified\":\"2026-06-01T07:03:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66967\"},\"wordCount\":564,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CF PharmTech\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2652\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66967#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66967\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66967\",\"name\":\"CF PharmTech's Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T07:03:38+00:00\",\"dateModified\":\"2026-06-01T07:03:39+00:00\",\"description\":\"CF PharmTech Inc. (HKG: 2652) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for ICF004 inhalation powder, a novel small interfering RNA (siRNA) drug with potential first-in-class mechanism of action for the treatment of interstitial lung disease (ILD). The therapy will be evaluated in multiple ILD subtypes, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), leveraging CF PharmTech's proprietary inhaled dry powder delivery platform to target diseased lung tissue directly while minimizing systemic exposure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66967#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66967\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66967#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CF PharmTech&#8217;s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CF PharmTech's Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease - Insight, China&#039;s Pharmaceutical Industry","description":"CF PharmTech Inc. (HKG: 2652) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for ICF004 inhalation powder, a novel small interfering RNA (siRNA) drug with potential first-in-class mechanism of action for the treatment of interstitial lung disease (ILD). The therapy will be evaluated in multiple ILD subtypes, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), leveraging CF PharmTech's proprietary inhaled dry powder delivery platform to target diseased lung tissue directly while minimizing systemic exposure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66967","og_locale":"en_US","og_type":"article","og_title":"CF PharmTech's Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease","og_description":"CF PharmTech Inc. (HKG: 2652) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for ICF004 inhalation powder, a novel small interfering RNA (siRNA) drug with potential first-in-class mechanism of action for the treatment of interstitial lung disease (ILD). The therapy will be evaluated in multiple ILD subtypes, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), leveraging CF PharmTech's proprietary inhaled dry powder delivery platform to target diseased lung tissue directly while minimizing systemic exposure.","og_url":"https:\/\/flcube.com\/?p=66967","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T07:03:38+00:00","article_modified_time":"2026-06-01T07:03:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66967#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66967"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CF PharmTech&#8217;s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease","datePublished":"2026-06-01T07:03:38+00:00","dateModified":"2026-06-01T07:03:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66967"},"wordCount":564,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CF PharmTech","Clinical trial approval \/ initiation","HKG: 2652"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66967#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66967","url":"https:\/\/flcube.com\/?p=66967","name":"CF PharmTech's Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T07:03:38+00:00","dateModified":"2026-06-01T07:03:39+00:00","description":"CF PharmTech Inc. (HKG: 2652) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for ICF004 inhalation powder, a novel small interfering RNA (siRNA) drug with potential first-in-class mechanism of action for the treatment of interstitial lung disease (ILD). The therapy will be evaluated in multiple ILD subtypes, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), leveraging CF PharmTech's proprietary inhaled dry powder delivery platform to target diseased lung tissue directly while minimizing systemic exposure.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66967#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66967"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66967#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CF PharmTech&#8217;s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66967"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66967\/revisions"}],"predecessor-version":[{"id":66969,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66967\/revisions\/66969"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}